Drug Profile
1- alpha hydroxyvitamin D5
Alternative Names: 1α-Hydroxy-Vitamin-D5; 1αVitD5; CARD-024Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Cardiavent
- Class Antineoplastics; Chemopreventatives; Small molecules; Vitamin D analogues
- Mechanism of Action Calcitriol receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Kidney disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cardiovascular-disorders(In volunteers) in USA (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Kidney-disorders(In volunteers) in USA (PO)
- 19 May 2015 CARD 024 development is ongoing in USA (Cardiavent Communication)